Pinealon vs Cerebrolysin
Both are Russian/CIS-origin neuropeptide compounds targeting cognitive-decline and neurological research applications, but they sit at very different points on the compound-architecture and evidence-base spectrum. Pinealon is a defined tripeptide bioregulator from the Khavinson St Petersburg research programme; Cerebrolysin is a complex multi-component porcine-brain peptide preparation with the broadest international clinical-trial evidence base in the Russian/CIS neuropeptide-preparation family.
At a glance
| Pinealon | Cerebrolysin | |
|---|---|---|
| Structural class | Tripeptide bioregulator (Glu-Asp-Arg) | Multi-component porcine-brain peptide preparation |
| Manufacturer / origin programme | Khavinson group (St Petersburg) | Ever Neuro Pharma (Austria) |
| Primary route | Oral (bioregulator formulation) or parenteral | Parenteral (intramuscular / intravenous) |
| Approving jurisdictions | Russia (bioregulator supplement framework) | Russia, China, CIS, Central/Eastern Europe |
| UK status | No emc entry found (checked 17 October 2026) | No emc entry found (checked 17 October 2026) |
| Clinical evidence base | Preclinical primary; limited human evidence | Substantial international RCT and meta-analytic evidence |
| Evidence tier | C | B |
| Signature mechanism | Short-peptide bioregulator activity, epigenetic modulation angle | Multi-component neurotrophic-mimicry, pleiotropic effects |
Compound-architecture positioning
Defined tripeptide versus multi-component preparation
Pinealon's compound architecture is that of a defined tripeptide (Glu-Asp-Arg) — a single molecule with defined structure, controlled synthesis, and defined pharmacokinetic characterisation. This architecture places Pinealon within the Khavinson short-peptide bioregulator research programme, which posits that short-peptide sequences derived from specific tissue types can modulate gene expression and downstream physiological function relevant to age-related decline in those tissues.
Cerebrolysin's compound architecture is that of a multi-component peptide preparation — a complex mixture of low-molecular-weight peptides, free amino acids, and other bioactive components produced by controlled proteolytic digestion of purified porcine brain tissue. The preparation is not a single molecule but a defined-composition biological product, with the manufacturing process (Ever Neuro Pharma) controlling batch-to-batch consistency.
This architectural difference has implications for how each compound's pharmacology is characterised. Pinealon can be studied with standard pharmacokinetic and dose-response methodology suitable for a defined tripeptide. Cerebrolysin's multi-component composition requires characterisation of composite biological activity rather than single-molecule pharmacology, and its mechanism-of-action framing operates through pleiotropic neurotrophic-mimicry rather than specific receptor engagement.
Evidence-base positioning
Preclinical primary versus substantial international clinical evidence
Pinealon's evidence base is predominantly preclinical — rodent cognitive-endpoint testing, biomarker characterisation, and mechanism-of-action work primarily from the Khavinson research programme. Human cognitive-endpoint clinical trial evidence is limited relative to the preclinical body. The compound is available in Russia through the bioregulator supplement framework rather than as a licensed clinical pharmaceutical.
Cerebrolysin's evidence base is substantial and international — the broadest RCT and meta-analytic body of any of the Russian/CIS multi-component neuropeptide preparations, with Cochrane systematic-review coverage of the vascular dementia, acute ischaemic stroke, and Alzheimer's disease indications. The evidence is not strong enough by Western regulatory-science standards to support licensed clinical use in these indications, but it provides substantially stronger clinical-context motivation than Pinealon's evidence base does.
For research applications the two compounds serve different roles. Pinealon is a research-tool for probing short-peptide-bioregulator hypotheses in cognitive-decline model systems. Cerebrolysin is a translational research-tool for clinical-application-adjacent research on multi-component neurotrophic-mimicry approaches to cognitive-decline intervention.